BICO Group AB (publ) (BICO) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to BICO Q3 2025 report presentation. For the first part of the presentation, participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now I will hand the conference over to the speakers, CEO Maria Force and CFO Jacob Thordenberg. Please go ahead. Hello and welcome to BICO Group's Q3 2025 Earnings Call. I'm Maria Forbes, President and CEO, and I will, together with BICO's CFO Jakob Thorndenberg, present this interim report. Here's today's agenda. I will open today's session by presenting how BICO serves the world's leading pharma and biotech companies with solutions that transform how labs operate and innovate. Following that, Jakob will provide a summary of the quarter's key developments and present the Group's financial performance. We'll proceed and comment on our two business areas, Life Science Solutions and Lab Automation. Additionally, we will highlight our R&D pipeline with ongoing product development efforts. And this session will conclude with final remarks before opening up for Q&A. At Baico, we serve the world's leading pharma biotech companies. Our portfolio ranges from Baicero's market leading Green Button Go software, enabling full lab orchestration, to off-the-shelf automation products and bioprinting from our life science solutions business. Our solutions enable smarter, faster, and more efficient labs, and here lies an underlying strong demand. Pharma and biotech companies face the same fundamental challenge, long and costly development cycles for new therapies. And the development of a new therapy often takes more than 10 years and costs between 2 and 4 billion US dollars, where 90% of the pipeline ultimately fails. To overc...